Psilocybin biosynthesis enhancement through gene source optimization.
Metabolic Engineering April 16, 2025 Madeleine R Keller, Madeline G. Mckinney, Abhishek K. Sen et al. 8 citations
Psilocybin, the prodrug to the psychoactive compound in 'magic' mushrooms, is currently being studied in clinical trials as a treatment for severe mental health conditions, such as depression and anxiety. Previous reports of psilocybin biosynthesis as reconstituted in E. coli reported maximum titers of 1.16 g/L, exclusively using genes from the most common recreationally used mushroom,...
DOI: 10.1016/j.ymben.2025.04.003 (opens in new tab)
Full text (opens in new tab)
Gene source optimization
Gymnopilus dilepis
Norbaeocystin methyltransferase
Promoter library
+7